Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Predictive Value Of Spectral Computed Tomography Parameters For Egfr Gene Mutation In Non-small-cell Lung Cancer.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Predictive Value Of Spectral Computed Tomography Parameters For Egfr Gene Mutation In Non-small-cell Lung Cancer.

Related Experiment Video

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Predictive value of spectral computed tomography parameters for EGFR gene mutation in non-small-cell lung cancer.

Y Yu1, C Han2, X Gan3

  • 1Department of Radiology, The First Affiliated Hospital of Xinjiang Medical University, Urumchi 830011, China; Department of Radiology, Xinjiang Medical University Affiliated Tumor Hospital, Urumchi 830011, China.

Clinical Radiology
|May 26, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Spectral CT parameters can help predict EGFR mutations in non-small cell lung cancer (NSCLC). Findings indicate intrapulmonary metastasis, distant metastasis, and venous phase iodine concentration are key indicators for EGFR mutations.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K

Related Experiment Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K

Area of Science:

  • Radiology and Imaging
  • Oncology
  • Molecular Diagnostics

Background:

  • Epidermal Growth Factor Receptor (EGFR) gene mutations are crucial in non-small cell lung cancer (NSCLC) treatment selection.
  • Accurate pre-operative prediction of EGFR mutation status can optimize treatment strategies for intermediate and advanced NSCLC.
  • Spectral computed tomography (CT) offers advanced imaging capabilities for characterizing tumors.

Purpose of the Study:

  • To evaluate the predictive value of spectral CT morphological signs and quantitative parameters for EGFR gene mutations in intermediate and advanced NSCLC.
  • To identify key imaging features that correlate with EGFR mutation status.

Main Methods:

  • Retrospective observational study of 79 patients with intermediate or advanced NSCLC.
  • Patients were categorized into EGFR mutation-positive and -negative groups.
  • Analysis included morphological signs and quantitative spectral CT parameters such as normalized iodine concentration (NIC) and slope of the energy spectrum curve (λ).

    • Main Results:

    • Significant differences were observed in pathological stage, tumor diameter, metastasis patterns (intrapulmonary, mediastinal lymph node, distant, bone), and spectral CT parameters between EGFR mutation-positive and -negative groups.
    • Multivariable logistic regression identified intrapulmonary metastasis, distant metastasis, venous phase NIC, venous phase λ, and pathological stage as independent predictors of EGFR mutations.
    • The combined model demonstrated high diagnostic power with an AUC of 0.975, 91.5% sensitivity, and 90.6% specificity.

    Conclusions:

    • Pathological stage combined with spectral CT parameters (intrapulmonary metastasis, distant metastasis, venous phase NIC, venous phase λ) can effectively predict EGFR gene mutations pre-operatively in intermediate and advanced NSCLC.
    • These imaging findings may guide non-invasive assessment of EGFR mutation status, aiding in personalized treatment planning.